References
- Song P, Gao J, Inagaki Y, et al. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012 Feb;1(1):3–9.
- Schieppati A, Henter JI, Daina E, et al. Why rare diseases are an important medical and social issue. Lancet. 2008 Jun 14;371(9629):2039–2041.
- Tang W. Hopes for intractable and rare diseases research. Intractable Rare Dis Res. 2013 Feb;2(1):1–2.
- Rare Diseases Europe. About rare disease. 2009 [cited 2015 Dec 10]. Available from: http://www.eurordis.org/about-rare-diseases.
- Mei L, Song P, Kokudo N, et al. Current situation and prospects of newborn screening and treatment for Phenylketonuria in China – compared with the current situation in the United States, UK and Japan. Intractable Rare Dis Res. 2013 Nov;2(4):106–114.
- Mei L, Song P, Xu L. Newborn screening and related policy against Phenylketonuria in China. Intractable Rare Dis Res. 2013 Aug;2(3):72–76.
- Song P. The ice bucket challenge: the public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseases. Intractable Rare Dis Res. 2014 Aug;3(3):94–96.
- Song P, Gao J, Inagaki Y, et al. Intractable and rare diseases research in Asia. Biosci Trends. 2012 Apr;6(2):48–51.
- Song P, Kokudo N. Revision of measures to combat intractable diseases in Japan: three pillars will play an even greater role in the future. Intractable Rare Dis Res. 2013 Feb;2(1):33–34.
- Song P, Gao J, Kokudo N, et al. New opportunity for orphan drug development in Japan: early exploratory clinical trial bases promote drug translation from basic studies to clinical application. Intractable Rare Dis Res. 2012 May;1(2):95–97.
- Inagaki Y, Song P. Necessity of cooperation with government on publication of scientific research results for intractable diseases. Intractable Rare Dis Res. 2013 May;2(2):69–71.
- Tang W, Makuuchi M. Intractable & rare diseases research. Intractable Rare Dis Res. 2012 Feb;1(1):1–2.
- The Ministry of Health and Welfare. The outline of strategy against intractable diseases [Internet]. 1972 [cited 2015 Dec 20]. Available from: http://www.nanbyou.or.jp/pdf/nan_youkou.pdf
- Japan Intractable Diseases Information Center. Strategies against intractable disease since 2015 [Internet]. 2015 [cited 2016 Jan 3]. Available from: http://www.nanbyou.or.jp/entry/4141.
- Japan Intractable Diseases Information Center. Number of patient enrolled specified disease treatment research program [Internet]. 2015 [cited 2016 Jan 5]. Available from: http://www.nanbyou.or.jp/entry/1356.
- The Japanese Ministry of Health, Labor, and Welfare. Revision of measures to combat intractable diseases [Internet]. 2013 [cited 2016 Jan 5]. Available from: http://www.mhlw.go.jp/stf/houdou/2r9852000002udoe.html
- The Ministry of Health, Labour and Welfare. The results of early exploratory clinical trial bases for specific research areas [Internet]. 2011 [cited 2016 Jan 6]. Available from: http://www.mhlw.go.jp/stf/houdou/2r9852000001jym4.html.
- Japan Intractable Diseases Information Center. The program of applied research to combat rare diseases [Internet]. 2014 [cited 2016 Jan 5]. Available from: http://www.nanbyou.or.jp/entry/3627.
- Song P, Inagaki Y, Sugawara Y, et al. Perspectives on human clinical trials of therapies using iPS cells in Japan: reaching the forefront of stem-cell therapies. Biosci Trends. 2013 Jun;7(3):157–158.
- The MHLW Grants System. The research against intractable liver diseases [Internet]. 2013 [cited 2016 Jan 5]. Available from: http://mhlw-grants.niph.go.jp/niph/search/NIDD00do?resrchNum=201231041A
- Japan Intractable Diseases Information Center. The guideline for diagnosis and treatment [Internet]. 2015 [cited 2016 Jan 6]. Available from: http://www.nanbyou.or.jp/entry/504#01.
- Japan Intractable Diseases Information Center. The center hospital for treatment of rare diseases [Internet]. 2014 [cited 2016 Jan 7]. Available from: http://www.nanbyou.or.jp/entry/1439.
- Japan Intractable Diseases Information Center. The cooperative hospital for treatment of rare diseases [Internet]. 2014 [cited 2016 Jan 7]. Available from: http://www.nanbyou.or.jp/entry/1611.
- Japan Intractable Diseases Information Center. Specified disease treatment research program on 130 diseases [Internet]. 2014 [cited 2015 Dec 28]. Available from: http://www.nanbyou.or.jp/entry/511
- Kodama T, Tomita N. Global movement for diagnosis and treatment of rare/intractable diseases. J Natl Inst Public Health. 2011;60:105–111. (in Japanese).
- Nakatani H, Kondo T. Characteristics of a medical care program for specific diseases in Japan in an era of changing cost-sharing. Health Policy. 2003 Jun;64(3):377–389.
- Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008 Sep 13;372(9642):889–890.
- Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013 Feb;18(3–4):163–172.
- Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010 Dec;9(12):921–929.
- Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011;6:62.
- Pharmaceuticals and Medical Devices Agency. The business report in 2010 [Internet]. 2010 [cited 2015 Dec 15]. Available from: https://www.pmda.go.jp/english/about-pmda/annual-reports/0001.html
- Tsuji K, Tsutani K. Personal imports of drugs to Japan in 2005 – an analysis of import certificates. J Clin Pharm Ther. 2008 Oct;33(5):545–552.
- Keio University Hospital Clinical and translation Research Center [Internet]. 2014 [cited 2015 Dec 27]. Available from: http://www.hosp.keio.ac.jp/ctr/about/outline.html
- Moritoyo T. Accelerating regulatory science initiatives for the development of drugs for Alzheimer’s disease in Japan. Clin Ther. 2015 Aug;37(8):1622–1626.